Shield is the first blood test approved by the U.S. Food and Drug Administration (FDA) as a primary screening option for CRC. The second leading cause of cancer-related deaths in the U.S., CRC has ...

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield blood test for colorectal cancer (CRC) screening has been named a winner of Fast Company’s 2025 ...

PALO ALTO, Calif., March 25, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now ...

PALO ALTO, Calif., March 25, 2025--Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced its Shield™ blood test for colorectal cancer (CRC) screening is now covered ...

Blood tests that detect early cancer are coming to market. Could they lead to earlier diagnosis and treatment?

This rate will be the payment amount for Shield from Jan. 1, 2026, to Dec. 31, 2027. The Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk ...

Guardant Health, Inc., a leading precision oncology company, today announced the Centers for Medicare& Medicaid Services has approved Advanced Diagnostic Laboratory Test status for the Shield ...

PALO ALTO, Calif. - Guardant Health, Inc. (NASDAQ:GH), a precision oncology company, announced that its Shield blood test for colorectal cancer (CRC) screening has been granted Advanced Diagnostic ...

The Shield blood test is FDA approved for primary non-invasive screening for colorectal cancer in average-risk individuals age 45 and older. For more information, visit www.ShieldCancerScreen.com.

Play (1min) Maks_Lab Guardant Health (NASDAQ: GH) said its recently approved blood test Shield for the detection of colorectal cancer has been commercially launched in the U.S.